ANDA Approval Times Get Optimistic Estimate In Budget Request
US FDA has historically overestimated generic review performance in budget requests, but recently underestimated the number of ANDAs it expects to approve.
You may also be interested in...
After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.
Only 8% of original ANDAs submitted in the user fee program’s third year were approved on the first cycle, compared with 72% that received a complete response letter.
CDER Director Woodcock says it may not be necessary for the ANDA first-cycle approval rate to approach that for NDAs, but lowering the number of cycles to two would be desirable.